BMS Pauses Zola-cel Autoimmune Studies
Bristol Myers Squibb confirmed that it paused autoimmune-disease studies of zolacabtagene autoleucel after life-threatening inflammatory and neurologic adverse events. The pause began in early June but became broadly public on September 4. The company…
